AstraZeneca PLC

AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.

prnewswire.com - 2026-07-16 10:07:00

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-07-16 10:00:00

AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed EGFR therapy.

zacks.com - 2026-07-15 13:05:24

On July 27, AstraZeneca PLC will report its results for the second quarter of 2026. As a reminder, its revenue rose 12.5% year-over-year to $15.29 billion in Q1. Enhertu, one of the key growth drivers of AstraZeneca's oncology franchise, generated $831 million in revenue in Q1, up 39.4% YoY and 4.1% QoQ.

seekingalpha.com - 2026-07-15 12:54:42

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-14 16:54:00

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform trial of Wainua failed to meet its primary endpoint in ATTR cardiomyopathy. If you held AZN and lost money, you are encouraged to  check your eligibility to recover losses now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

globenewswire.com - 2026-07-14 10:12:00

Solis Minerals Ltd (ASX:SLM, TSX-V:SLMN, OTCQB:SLMFF) has kicked off diamond drilling at the Mandacaru Lithium Project in Brazil, targeting a coherent...

proactiveinvestors.com - 2026-07-14 07:41:00

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal...

proactiveinvestors.com - 2026-07-14 04:16:00

ACG Metals Ltd (LSE:ACG, OTC:ACGAF), the London-listed gold, silver and copper group operating the Gediktepe operation in Türkiye, beat its full-year oxide...

proactiveinvestors.com - 2026-07-14 03:20:00

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has agreed to pay $600 million upfront to secure worldwide rights to a lung cancer pill developed by China's Dizal Pharmaceutical. The Cambridge-based drugmaker could pay a further $900 million if the treatment hits certain development, regulatory and sales targets.

proactiveinvestors.co.uk - 2026-07-14 03:18:02

AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.

wsj.com - 2026-07-14 02:55:00

AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one ​of its drugs for a type of ‌lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange Tuesday.

reuters.com - 2026-07-14 02:19:59

When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.

marketbeat.com - 2026-07-13 12:25:30

On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua mis

gurufocus.com - 2026-07-13 11:00:00

NEW YORK--(BUSINESS WIRE)--On July 9, 2026, AstraZeneca (NYSE: AZN) stock fell more than 8% premarket after the Company announced that the Phase III CARDIO-TTransform trial of Wainua missed its primary endpoint in ATTR cardiomyopathy. If you suffered a loss on your AstraZeneca investment, you are encouraged to submit your information here. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. Wainua, a gene-silencing drug for transthyr.

businesswire.com - 2026-07-13 10:07:00

HSBC has downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', arguing that a recent trial failure has removed the central pillar of its bull case and left a tougher path ahead. The bank cut its target price to 13,750p from 16,500p, implying limited upside.

proactiveinvestors.co.uk - 2026-07-13 08:11:48

UBS expects AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to report solid second-quarter results later this month, though it sees little room for the drugmaker to raise full-year guidance. The bank reiterated its 'buy' rating on Britain's second most valuable listed company, ahead of results due on 27 July.

proactiveinvestors.co.uk - 2026-07-13 07:36:19

Astrazeneca NYSE: AZN told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs.

marketbeat.com - 2026-07-11 19:03:01

AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years. Analysts estimate the trial miss wiped just 2-4% from their valuation models but the market reaction suggested it was about more than a single drug.

cnbc.com - 2026-07-11 01:00:01

The latest trading day saw Astrazeneca (AZN) settling at $171.61, representing a -3.85% change from its previous close.

zacks.com - 2026-07-10 19:16:05

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) said on Thursday that their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

benzinga.com - 2026-07-10 11:30:43

/PRNewswire/ -- On July 9, 2026, AstraZeneca (NYSE: AZN) shares fell approximately 8.4% before the market opened after the Phase III CARDIO-TTransform trial of

prnewswire.com - 2026-07-10 09:00:00

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of affected AZN investors.

prnewswire.com - 2026-07-09 20:58:00

AstraZeneca PLC shares fell >6% after Wainua (eplontersen) failed its Phase 3 ATTR-CM trial, missing a major revenue opportunity. The stock of Ionis Pharmaceuticals, Inc., developer of eplontersen and in line for royalties on sales of eplontersen, also fell by >20%. AZN's ambitious $80bn 2030 revenue target now faces a ~$15bn gap by my calculation, but a robust late-stage pipeline and strong oncology division provide resilience.

seekingalpha.com - 2026-07-09 15:58:21

AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.

zacks.com - 2026-07-09 10:56:13

The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent to management's credibility, according to Jefferies. The shares fell 9% and topped the FTSE 100 fallers' list, a move the broker expects to exceed the drug's actual contribution to valuation.

proactiveinvestors.co.uk - 2026-07-09 09:29:06

Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset sluggish sales in North America; Korean memory chip maker SK Hynix is reportedly seeing heavy demand for its upcoming U.S. stock listing; AstraZeneca shares are sinking after a disappointing heart drug trial; and Levi Strauss shares are falling after the denim apparel maker issued weak guidance. Here's what you need to know today.

investopedia.com - 2026-07-09 08:35:47

The UK's FTSE 100 declined on Thursday as investors assessed renewed tensions in the Middle East, while pharmaceutical heavyweight AstraZeneca weighed heavily on the benchmark after reporting disappointing results from a late-stage clinical trial. The blue-chip FTSE 100 index fell 0.6% to 10,417.63 points by 10:45 GMT.

invezz.com - 2026-07-09 08:12:14

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and partner AstraZeneca Plc (NYSE:AZN) on Thursday said their Phase 3 CARDIO-TTRansform study of eplontersen for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) failed to meet its primary efficacy endpoint.

benzinga.com - 2026-07-09 08:09:28

AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.

barrons.com - 2026-07-09 07:38:00

AZN drops as drug trial misses expectations, SK Hynix set for huge U.S. ADR listing, and more

fool.com - 2026-07-09 07:30:00

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a...

proactiveinvestors.com - 2026-07-09 04:50:00

AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective in a late-stage clinical trial for a serious heart condition, dealing a setback to one of its most closely watched pipeline assets. The stock fell about 9.5% in London trading, making it the biggest loser on the FTSE 100 index.

invezz.com - 2026-07-09 04:49:25

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a closely watched Phase III trial in a form of heart disease. The drop propelled the stock to the top of the FTSE 100 losers' list.

proactiveinvestors.co.uk - 2026-07-09 03:50:21

AstraZeneca stock dives 9% after heart drug trial misses target

cnbc.com - 2026-07-09 03:34:08

The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo.

wsj.com - 2026-07-09 02:59:00

AstraZeneca said ​on Thursday ‌that its drug ​Wainua, ​made in partnership ⁠with ​Ionis , ​failed to meet the ​main ​goal of reducing ‌cardiovascular ⁠deaths and recurring heart ​problems ​in ⁠a late-stage ​trial.

reuters.com - 2026-07-09 02:12:37

Drugmakers AstraZeneca and Daiichi Sankyo are nearing an agreement ​with the UK's pricing regulator for their breast cancer treatment ‌Enhertu, Bloomberg News reported on Wednesday, citing multiple people familiar with the matter.

reuters.com - 2026-07-08 08:53:15

Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.

wsj.com - 2026-07-07 23:44:00

Hong Kong-listed Sino Biopharmaceutical said on Wednesday it ​has granted AstraZeneca the ‌rights to develop a drug designed to treat chronic respiratory ​diseases outside China for ​total payments of up to $1.9 ⁠billion.

reuters.com - 2026-07-07 18:48:59

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

zacks.com - 2026-07-07 10:06:11

AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation Transcript

seekingalpha.com - 2026-07-06 13:12:41

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has been kept on a 'buy' rating by Citi, which pointed to a run of late-stage drug trial results in the second half of...

proactiveinvestors.com - 2026-07-06 09:03:00

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has been kept on a 'buy' rating by Citi, which pointed to a run of late-stage drug trial results in the second half of the year as the key driver for the shares. The Wall Street bank was previewing second-quarter results from the Anglo-Swedish pharmaceuticals group, due on 27 July.

proactiveinvestors.co.uk - 2026-07-06 08:06:44

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

fool.com - 2026-07-03 08:37:20

On July 02, 2026, AstraZeneca PLC (AZN) shares rose 6.1% today to a current price of $195.15. The stock has performed well over the past year, showing a signifi

gurufocus.com - 2026-07-02 17:19:00

Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc (NYSE:AZN) to jointly develop a novel combination therapy for patients with EGFR-mutated and PD-L1 positive non-small cell lung cancer (NSCLC).

benzinga.com - 2026-07-02 13:05:42

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-07-02 10:40:45

AstraZeneca has entered into a deal ​worth up to $1.77 billion with CSPC ‌Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, ​the Chinese drugmaker said on ​Thursday.

reuters.com - 2026-07-02 06:16:16

SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC).

prnewswire.com - 2026-07-01 21:00:00